ProstaLund Investor Relations Material
Latest events
Q4 2024
ProstaLund
Q2 2025
21 Aug, 2025
Q1 2025
30 May, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from ProstaLund
Access all reports
ProstaLund AB develops and sells urological devices for the treatment of patients with benign prostatic hyperplasia (BPH) internationally. The company offers BeeVital, a non-surgical therapy for BPH. It also provides Revive Flow, a laser treatment for neurogenic bladder; and Revive Basal, a drug for neurogenic bladder. The company distributes its products in the United States, Latin America, Canada, Europe, and Australia through specialized support centers. ProstaLund is hardquartered in Lund, Sweden.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
PLUN
Country
🇸🇪 Sweden